{
    "nctId": "NCT02777580",
    "officialTitle": "STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction",
    "inclusionCriteria": "1. Age equal or greater than 60 years\n2. Onset of symptoms \\< 3 hours prior to randomisation\n3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J point; scale: 1 mm per 0.1 mV):\n\n   * \u2265 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of \u2265 4 mm ST-elevation or\n   * \u2265 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of \u2265 4 mm ST-elevation\n4. Informed consent received\n* Must have minimum age of 60 Years",
    "exclusionCriteria": "1. 1. Expected performance of PCI \\< 60 minutes from diagnosis (qualifying ECG) or inability to arrive at the catheterisation laboratory within 3 hours\n2. Previous CABG\n3. Left bundle branch block or ventricular pacing\n4. Patients with cardiogenic shock - Killip Class 4\n5. Patients with a body weight \\< 55 kg (known or estimated)\n6. Uncontrolled hypertension, defined as sustained blood pressure \u2265 180/110 mm Hg (systolic BP \u2265 180 mm Hg and/or diastolic BP \u2265 110 mm Hg) prior to randomisation\n7. Known prior stroke or TIA\n8. Recent administration of any i.v. or s.c. anticoagulation within 12 hours, including unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral anticoagulation (i.e. warfarin or a NOACs)\n9. Active bleeding or known bleeding disorder/diathesis\n10. Known history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \\< 3 months)\n11. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction)\n12. Clinical diagnosis associated with increased risk of bleeding including known active peptic ulceration and/or neoplasm with increased bleeding risk\n13. Prolonged cardiopulmonary resuscitation (\\> 2 minutes) within the past 2 weeks\n14. Known acute pericarditis and/or subacute bacterial endocarditis\n15. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis\n16. Dementia\n17. Known severe renal insufficiency\n18. Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days\n19. Known allergic reactions to tenecteplase, clopidogrel, enoxaparin and aspirin\n20. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated."
}